20 Minutes delay
- Share Prices
Price-sensitive announcements are indicated in red/hot pink colour.
|Company Name||INCANNEX HEALTHCARE LIMITED|
|Official Listing Date||2007-05-23|
Incannex Healthcare Limited (ASX: IHL) is a first-in-class innovator and developer of a diversified mix of medicinal cannabis pharmaceutical products for global export potential and long-term value creation.
Incannex is currently undertaking clinical programs to develop 4 uniquely formulated medicinal cannabis products for the treatment of Obstructive Sleep Apnoea (OSA_IHL-42X), Traumatic Brain Injury/Concussion (TBI_IHL-216A), Temporomandibular Joint Disorder (TMJD_IHL-493C), and sepsis-associated Adult Respiratory Distress Syndrome (SAARDS_IHL-675A).
Each indication represents major global markets representing total addressable markets of billions of dollars per annum. 3 of the 4 indications currently have no existing registered pharmacotherapy (drug) treatment, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profile in clinical trials.
There is an established body of research evidence validating the hypothesis for the cannabinoids being used in Incannex’s chosen therapeutic areas and IHL has a strong patent filing strategy as it develops its products in conjunction with its medical advisory board of global key opinion leaders.
Further to its clinical programs, Incannex also has its Australian licenses in place to import, export and distribute medicinal cannabis products and has launched a line of EU GMP approved CBD oil products under the brand, “INCANNEX”. The INCANNEX cannabis-based oils are sold under Incannex’s product supply and distribution agreement with Cannvalate Pty Ltd, which is the largest network of cannabis medicine prescribers in Australia.